NEW YORK (GenomeWeb News) – GenMark Diagnostics today announced that it has acquired a non-exclusive license to Innogenetics' hepatitis C virus genotyping patent estate in the US.
The deal includes an option to extend the license globally. Other terms were not disclosed.
According to GenMark, though HCV genotyping is a guideline-supported test performed in combination with HCV screening and viral load testing, US laboratories have limited molecular diagnostic technology options in this area.
"We believe that this license will allow us to enter a market that is ideally suited to our technology and will significantly increase the value of the XT-8 system for our customers," said Chris Gleeson, chairman and CEO of GenMark.
A number of companies are developing HCV molecular diagnostic tests, and among those that provide a molecular diagnostic test for HCV are Roche, which last week said that the US Food and Drug Administration cleared its second-generation real-time PCR Cobas TaqMan HCV Test. Siemens Healthcare also received the thumbs-up from the FDA for an HCV monitoring test in 2008.
Gleeson added that the addition of HCV genotyping to GenMark's diagnostics test menu is anticipated to accelerate the Carlsbad, Calif.-based company's expansion into the largest molecular diagnostics laboratories in the US.